Author

Manoj Kumar Khera

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Cameron W. A. SnyderiD· 3 shared Kyukwang KimiD· 3 shared Michael W. BeckeriD· 3 shared Myla S. StrawdermaniD· 3 shared Negar KhazaniD· 3 shared Niloy A. Singh· 3 shared Rachael B. Rowswell-TurneriD· 3 shared Rakesh K. SinghiD· 3 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Cameron W. A. SnyderORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

IL1β/IL1R1/IRAK4 Drives Inflammatory Ovarian Cancer Seeding at the inflamed sites and Is Reversed by an IRAK4 inhibitor UR241-2

J. Miller, Kyukwang Kim, Cameron W. A. Snyder, Negar Khazan, Niloy A. Singh, Megan E. Boyer, Elizabeth A. LaMere, Myla Strawderman, Sonali Sharma, Ronald Lakony, Michelle Whittum, Mark Anderson, Rick Keenan, Elizabeth Pritchett, Cameron Baker, , Rakesh K. Singh

This paper identifies the IL1β/IL1R1/IRAK4 axis as critical for inflammation-driven ovarian cancer metastasis and shows that IRAK4 inhibition with UR241-2 reduces tumor seeding and activates antitumor immune responses.

bioRxiv · May 5, 2026 · PreprintCancer Biology

PSP-0119: Targeted IRAK4 Degradation as a Novel Therapeutic Strategy for FLT3-Mutant AML

Negar Khazan, Cameron W. A. Snyder, Chandhana Ravi, Elizabeth A. LaMere, Niloy A. Singh, Manoj Kumar Khera, Jane L. Liesveld, Srinivasan Ekambaram, Nikolay V. Dokholyan, Myla S. Strawderman, Kyukwang Kim, Rachael B. Rowswell-Turner, Michael W. Becker, Richard G. Moore, Rakesh K. Singh

This study identifies PSP-0119, an IRAK4 degrader, as a promising therapy for FLT3-mutant AML by inhibiting IRAK4 activity and showing antileukemic effects in cell lines and xenograft models.

bioRxiv · Sep 30, 2025 · PreprintCancer Biology

IL-1β/IRAK4 Axis Promotes Ovarian Tumor Development at the Mesothelium Injury Sites

John P. Miller, Kyukwang Kim, Negar Khazan, Cameron W. A. Snyder, Niloy A. Singh, Elizabeth Lamere, Myla S. Strawderman, Sonali Sharma, Ronald Lakony, Michelle Whittum, Mark Anderson, Rick Keenan, Elizabeth Pritchett, Cameron D. Baker, John M. Ashton, , Rakesh K. Singh

This paper develops a MIM model to study EOC metastasis at mesothelial injury sites and shows IRAK4 inhibitors reduce tumor burden more effectively than IL-1/IL-1R1 targeting agents.

bioRxiv · Mar 18, 2025 · PreprintCancer Biology